Is Biotech Poised for Upside Continuation?

My near-term work in XBI (SPDR Biotech ETF) argues for one more upleg into new, high territory prior to a significant correction.

I have two constructive scenarios:

 1) an upside thrust from above 77.00-76.80 micro support towards my next target of 82.00-83.00, or

 2) a press into the area of the sharply-rising 2-0 DMA, now at 75.41, prior to the emergence of the anticipated upleg to 82-83.

Take Advantage Of Our Free
7-Day Trial, $71st Month Offer!
  • Action-Oriented Trade Set-Ups in Stocks & ETFs
  • Macro Analysis of the Broader Markets
  • Detailed Technical Guidance for each Trading Idea
  • Live Interaction w/ Mike & Our Member Community
  • And Much, Much More!
Join Now! - Special Offer!
Veteran Wall Street analyst and financial author, Mike provides detailed and timely analysis and trade set-ups on a range of markets. Read more...

Have Mike's “Out Front” morning analysis delivered FREE to your email inbox twice weekly!